ptp1bin3

PTP1B-IN-3 is a selective and potent PTP1B inhibitor with anticancer activity that inhibits PTP1B and TCPTP.PTP1B-IN-3 is used in the study of diabetes.

PTP1B-IN-30 (Compound 3j) is an inhibitor of PTP1B with an IC50 of 0.51 µM. It suppresses the proliferation of T47D cancer cells with an IC50 of 21.21 µM, induces cell cycle arrest at the S phase, and triggers apoptosis in T47D cells.

PTP1B-IN-31 (Compound (S,S)-3ak) is a PTP1B inhibitor with an IC50 of 0.81 μM. It works synergistically with cytokine IFNγ to inhibit the growth of tumor cells, making it useful for cancer research.

PTP1B-IN-33 is a protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 2.45 μM against human PTP1B, showing more than 20-fold selectivity over SHP2. It enhances π-alkyl interactions with PTP1B, thereby promoting closure of the WPD loop. PTP1B-IN-33 can be used in studies on cancer, diabetes, and autoimmune deficiency diseases.

PTP1B-IN-34 is an orally active, selective, and non-competitive inhibitor of PTP1B, with an IC50 value of 0.64 μM and a Ki of 1.15 μM for human PTP1B. It effectively reduces blood glucose levels in diabetic mice and is applicable for research related to type 2 diabetes.

PTP1B-IN-3 diammonium is a highly effective and orally bioavailable inhibitor of the protein tyrosine phosphatase 1B (PTP1B) enzyme, with an IC50 value of 120 nM for both PTP1B and TCPTP, exhibiting potent antidiabetic and anticancer properties, as supported by extensive research [1] [2].